Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
VERACYTE, INC. reported the full year ended December 31, 2023 results: revenue between $358.0 million and $359.0 million.
- Period
- the full year ended December 31, 2023
- Revenue
- between $358.0 million and $359.0 million
- Result
- preliminary results
Exact text from the filing
For the full year ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $358 million and $359 million, an increase of 21%
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
VERACYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $95.0 million and $96.0 million.
- Period
- the fourth quarter ended December 31, 2023
- Revenue
- between $95.0 million and $96.0 million
- Result
- preliminary results
Exact text from the filing
For the fourth quarter ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $95 million and $96 million, an increase of between 18% and 20%
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
VERACYTE, INC. reported full year 2024 results: revenue between $394 million and $402 million. Guidance initiated.
- Period
- full year 2024
- Revenue
- between $394 million and $402 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Veracyte is initiating 2024 testing and product revenue guidance of 13% to 15% growth, partially offset by declining biopharma and other revenue, resulting in total company revenue growth of 10% to 12%, or $394 million to $402 million.
View on SEC.gov